奈达铂联合紫杉醇和顺铂联合紫杉醇同步放化疗局部晚期鼻咽癌的临床随机对照实验

Randomized controlled trials of nedaplatin combined with paclitaxel and cisplatin paclitaxel in concurrent chemoradiotherapy for local advanced nasopharyngeal carcinoma

目的通过临床随机对照实验观察奈达铂是否能够替代顺铂与紫杉醇联合同步放化疗局部晚期鼻咽癌，是否能够提高治疗的耐受性。方法实验组（TN组）30例，采用紫杉醇135mg／m2。ivgttdl＋奈达铂10mg／m2ivgttd1诱导化疗，每3周为1个化疗周期，共2个疗程，以后行同样方案同期放化疗，仍然每3周为1个化疗周期，共2个疗程。对照组（TP组）30例，采用顺铂（30mg／m2，ivgtt，d1～3）代替奈达铂，余治疗方法同实验组。结果两组有效率相似，实验组不良反应明显降低。结论奈达铂联合紫杉醇结合同步放疗治疗局部晚期鼻咽癌疗效确切，且患者耐受性良好。

Objective To explore whether nedaplatin combined with paelitaxel can replace cisplatin plus paclitaxel in concurrent chemoradiotherapy for local advanced nasopharyngeal cancer, and whether it can improve the tolerance of treatment. Methods Thirty patients in the experimental group （TN group） were given paclitaxel （135 mg/m2 ivgtt dl） and nedaplatin （10 mg/m2 ivgtt dl）. every 3 weeks for a chemotherapy cycle, a total of 2 courses, after the same program line chemoradiotherapy still every 3 weeks for a chemotherapy cycle, a total of 2 courses. Thirty patients in the control group （TP group） received cisplatin （30 ivgtt mg/m2 d 1-3 ） instead of nedaplatin, and the other treatments were the same with the experimental group. Results The efficiency of the two groups was similar, but the side effects in experimental group were significantly reduced. Conclusion The combination of nedaplatin combined with paclitaxel and concurrent radiother- apy is an effective treatment for local advanced nasopharyngeal carcinoma, and patients are well tolerated.